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Abstract  Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal growth factor 
receptor 2 (HER2) and inhibits dimer formation. The combined use of pertuzumab and trastuzumab for HER2-positive breast 
cancer has been reported to significantly increase the rate of pathological complete response (pCR) compared to that with 
trastuzumab monotherapy. We reported the outcomes of HER2-positive breast cancer treated with neoadjuvant chemotherapy 
with pertuzumab. Sixteen patients with stages II–III HER2-positive breast cancer were treated with 4 cycles of docetaxel (75 
mg/m2) with trastuzumab and pertuzumab, followed by 4 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and 
cyclophosphamide (500 mg/m2). The participants were in the age range of 45–76 years; T1, T2 and T3 stages were reported in 
2, 11, and 3 cases, respectively, and N0 and N1 stages were reported in 6 and 10 cases, respectively. Luminal HER2 and HER2-
enriched subtypes were noted in 8 cases each. In all cases, scheduled chemotherapy was completely implemented. Grade 3, 2b, 
1a and 1b histology were observed in 11, 3, 1, and 1 cases, respectively. The rate of pCR (ypT0/is + ypN0) was 69%, whereas 
the objective response rate was 94%. In 12 cases, breast-conserving surgery was undertaken, whereas 4 patients underwent 
total mastectomy. Pertuzumab did not cause any complications, including cardiac dysfunction. 




Neoadjuvant chemotherapy is increasingly being 
administered to patients with locally advanced breast 
cancer as well as to patients with operable breast 
cancer, to facilitate downstaging for breast-
conserving surgery. Survival outcomes of such a 
strategy were reported to be comparable to those of 
adjuvant chemotherapy[1]. The human epidermal 
growth factor receptor 2 (HER2) is overexpressed 
and/or its gene is amplified in 15–20% of breast 
cancers; overexpression and/or gene amplification is 
associated with a high risk of breast cancer recurrence 
and metastasis[2]. The standard-of-care neoadjuvant 
regimens for the treatment of HER2-positive breast 
cancer comprise conventional systemic chemotherapy 
plus trastuzumab-based therapy[3]. The rate of 
pathological complete response (pCR) with 
conventional systemic chemotherapy plus HER2 
blockade range from 25% to 65%, with dual HER2-
targeted regimens producing higher pCR rates than 
trastuzumab monotherapy[4-6]. pCR in the breast and 
nodes is associated with prolonged event-free 
survival and overall survival (OS) in patients with 
HER2-positive breast cancer[3, 7].  
This report presents a case series of 16 patients 
with HER2-positive breast cancer treated with 
neoadjuvant chemotherapy with pertuzumab. 
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Case reports 
Between October 2013 and April 2019, 16 patients 
with HER2-positive breast cancer, stages II–III (T1–
3, N0–1, M0) and an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1 were 
enrolled (Table 1). The median age in this report 
population was 58 (range 45–76) years, and the 
median tumor size was 35 (range 18–65) mm. All 
patients underwent pretreatment core needle or 
vacuum-assisted biopsy and were diagnosed with 
invasive cancer. Clinical T1, T2, and T3 disease were 
noted in 2(12%), 11 (69%), and 3 (19%) patients, 
respectively. Eight (50%) patients each had hormone 
receptor (HR)-positive and HR-negative breast cancer. 
HER2-positive status was defined as 3+ 
overexpression detected on immunohistochemical 
testing or HER2 amplification on fluorescence in situ 
hybridization. Neoadjuvant chemotherapy consisted 
of 4 cycles (every 3 weeks) of docetaxel (75 mg/m2) 
with trastuzumab (loading dose 8 mg/kg, followed by 
6 mg/kg) and pertuzumab (loading dose 840mg, 
followed by 420 mg), followed by 4 cycles (every 3 
weeks) of the FEC regimen (5-fluorouracil, 500 
mg/m2; epirubicin, 100 mg/m2; and cyclophosphamide, 
500 mg/m2) . The protocol was approved by the 
Institutional Cancer Medical Promotion Committee. 
All patients provided written informed consent prior 
to treatment initiation. 
All patients completed the chemotherapy on 
schedule, and received primary prophylaxis with 
granulocyte-colony stimulating factor (G-CSF). The 
incidence of treatment-related adverse events is 
summarized in Table 2. Hematological toxicity 
manifested as anemia and hepatic dysfunction in 1 
(6%) and 3 (19%) patients, respectively. Non-
hematological toxicities, such as peripheral 
neuropathy (100%; n = 16), nausea (31%; n = 5), and 
stomatitis, skin eruption and arthralgia (25%; n = 4) 
were observed. Peripheral neuropathy in 2 patients 
(13%) was reported as the only grade 3/4 toxicity. 
None of the patients developed clinically 
symptomatic heart failure or cardiac dysfunction. 
Clinical response was evaluated using two-
dimensional measurements on magnetic resonance 
imaging or ultrasonography according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST)[8]. Histological response after the 
completion of the chemotherapy regimen was 
evaluated according to the histopathological criteria 
for the assessment of therapeutic response in breast 
cancer[9], based on breast and axillary lymph node 




Woman, n (%) 16 (100) 
Median age, years (range) 58 (45-76) 
Menopsusal status, n (%) 
 
  Premenopausal 5 (31) 
  Postmenopausal 11 (69) 
ECOG performance status, n (%)  
 
0 15 (94) 
1 1 (6) 
Histology, n (%) 
 
  Invasive ductal carcinoma 16 (100) 
  Invasive lobular carcinoma 0 (0) 
  Special types 0 (0) 
Clinical Tumor stage, n (%) 
 
  T1 2 (12) 
  T2 11 (69) 
  T3 3 (19) 
Clinical nodal stage, n (%) 
 
  N0 6 (37) 
  N1≦  10 (63) 
Subtype, n (%) 
 
  HER2-enriched 8 (50) 
  Luminal HER2 8 (50) 
ER; estrogen receptor, PgR; progesterone receptor, 
HER2; human epidermal growth factor receptor 
type 2, FISH; fluorescent in situ hybridization, 
ECOG; Eastern Cooperative Oncology Group 
 
 
resection specimens. For the purposes of this report, 
pCR was defined as no evidence of a residual invasive 
component in both the breast and axilla (Grade 3, 
ypT0/is yoN0).  
Eleven (69%) patients achieved pCR (ypT0/is 
ypN0). The rate of pCR for patients with HER2-
enriched and luminal HER2 subtypes were 63% (5/8) 
and 75% (6/8), respectively (Fig. 1). Based on the 
RECIST criteria, we observed complete response 
(CR) and partial response (PR) in 12 (75%) and 3 
(19%) patients, respectively, which corresponded to 
an objective response rate (ORR) of 94%. 
  Patients underwent definitive breast cancer surgery 
between 21 days and 6 weeks after the last dose of 
neoadjuvant therapy. Twelve (75%) patients 
underwent breast-conserving surgery, 3 patients 
(19%) underwent total mastectomy, and 1 patient 
underwent nipple conservative total mastectomy; the 
type of surgery was selected on a large amount of  
residual disease, patient preference, or a patient’s 
desire for breast reconstruction (Table 3). 
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  Within 8 weeks of surgery, patients resumed dual 
HER2-targeted therapy (trastuzumab and pertuzumab). 
Adjuvant radiotherapy and endocrine therapy were 
administered as clinically indicated the by the local 
practice. 
All patients treated with this regimen have 
remained healthy without any recurrence. 
 
Discussion 
Breast cancer patients who achieve pCR are known 
to have better long-term survival than patients who 
achieve a lower-grade response. In particular, patients 
with HER2-positive breast cancer who received 
chemotherapy in combination with trastuzumab 
showed a higher pCR rate, which was directly related 
to improved survival outcomes[3,7,10].  
Pertuzumab is a humanized monoclonal antibody 
that inhibits the dimerization of HER2 with other 
HE R- r e c e p to r s  ( H E R1– 4 ) .  T he  co mb ina t ion  o f 
pertuzumab and trastuzumab showed further benefits 
with significantly improved progression-free survival 
(PFS)/OS in patients with advanced breast cancer[11]. 
I n  t h e  N e o S p h e r e  s t u d y,  t h e  c o m b i n a t i o n  o f 
per tuzumab and trastuzumab plus docetaxel  was 
highly efficacious in the neoadjuvant setting, with an 
increase of  17.8% in pCR (ypT0/ is ypN0) rates, 
compared wi th the pCR rate of tras tuzumab plus 
docetaxel[4]. Similar benefits were demonstrated in 
the TRYPHAENA[5] and BERENICE[6] studies. At 
present ,  the  s tandard-of -care fo r  HER2-pos i t ive 
Fig. 1. The pCR rates according to Subtype 
 
Table 2. Summary of Adverse Events 
 
Event 
All grades Grade 3/4 
n  (%) n  (%) 
Nonhematological toxicities 
    
stomatitis 4  25  0  0  
anorexia 1  6  0  0  
nausea 5  31  0  0  
vomiting 1  6  0  0  
diarrhea 3  19  0  0  
skin eruption 4  25  0  0  
arthralgia and/or myalgia 4  25  0  0  
peripheral neuropathy 16  100  2  13  
infusion reaction 2  13  0  0  
cardiac disorders 0  0  0  0  
Hematologic toxicities 
    
anemia 1  6  0  0  
neutropenia 0  0  0  0  
febrile neutropenia 0  0  0  0  
thrombocytopenia 0  0  0  0  
hepatic dysfunction 3  19  0  0  
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Table 3. Therapeutic Results 
 
Parameter n (%) 
Histological response  
 
  Grade 3 (ypT0 ypN0) 9 (56) 
  Grade 3 (ypTis ypN0) 2 (12) 
  Grdae 2 3 (19) 
  Grade 1 2 (12) 
  Grade 0 0 (0) 
Overall response rate prior to surgery  
  CR 12 (75) 
  PR 3 (19) 
  SD 1 (6) 
  PD 
 
Definitive surgery  
 
  Mastectomy 4 (25) 
  Breast-conserving surgery  12 (75) 
pCR; pathological complete response, CR; 
complete response, PR; partial response, SD;  
stable disease, PD; progressive disease 
 
 
breast cancer stage M0 at primary diagnosis is 
neoadjuvant treatment with a combination of taxane-
containing chemotherapy and a dual blockade with 
pertuzumab and trastuzumab[12]. In this report, the 
administration of pertuzumab and trastuzumab plus 
docetaxel, followed by FEC regimen, resulted in a 
higher pCR rate (69%), and ORR (94%). 
In the present report, the rates of pCR for patients 
with HR-positive and HR-negative breast cancer were 
75% and 63%, respectively. A previous meta-analysis 
demonstrated a trend for higher pCR rates in non-
luminal HER2 tumors than in luminal HER2 
tumors[13]. Indeed, the pCR rates were 26% and 63% 
for HR-positive and HR-negative breast cancer, 
respectively, in the NeoSphere study[4], and 46–50% 
and 65–84%, respectively, in the TRYPHAENA 
study[5]. This discrepancy might be explained by the 
findings of a recent translational study, which showed 
that phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA) mutations are 
associated with reduced rates of pCR with anti-HER2 
therapy for HER2-positive tumors, regardless of HR 
status[14]. 
Clinicians are increasingly faced with challenges 
regarding how to efficiently use and sequence the 
multitude of therapies available for cancer. For 
example, if a patient achieves pCR following 
neoadjuvant pertuzumab-based therapy, pertuzumab 
therapy for 1 year along with trastuzumab in the 
adjuvant setting could be continued, or one could 
consider scaling back therapy and omitting further 
pertuzumab administration, given the prognostic 
significance of pCR. Furthermore, given the 
prognostic significance of pCR in HER2-positive 
disease, novel trial designs featuring a reduction in 
therapy after achieving pCR, or conversely, escalation 
of therapy when pCR is not achieved, are warranted. 
In recent years, the KATHERINE study[15] reported 
that the risk of recurrence of invasive breast cancer or 
death was 50% lower with adjuvant trastuzumab 
emtansine (T-DM1) than with trastuzumab alone 
among patients with HER2-positive early breast 
cancer who had residual invasive disease after 
completion of neoadjuvant therapy. The apparent loss 
of HER2-positive status in patients with residual 
disease after neoadjuvant therapy has been 
reported[16], although no studies were designed to 
specifically address the activity of pertuzumab and/or 
T-DM1 in this subgroup. 
The predictive accuracy of the therapeutic response 
could be improved in future clinical studies, though 
the stratification of intrinsic subtypes of HER2-
positive breast cancer by molecular biomarkers, such 
as PIK3CA mutations. In addition, further analyses 
should be concluded to define the rate of HER2 loss 
in postsurgical specimens. The lack of a control arm 
and the small sample size are key limitations of this 
report. 
In conclusion, neoadjuvant chemotherapy consisted 
of 4 cycles of docetaxel with trastuzumab  and 
pertuzumab followed by 4 cycles of the FEC regimen 
showed a higher rate of pCR and safety in patients 
with HER2-positive breast cancer. 
 
Consent for publication 
Informed consent for publication of this case report was 
obtained using the opt-out system. 
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Pertuzumab を用いた術前化学療法を施行した 16 例 
阿部 元 1)、寺本敦子 1)、竹井裕美子 1)、米田光里 1)、田中義人 2) 
1) ベルランド総合病院 乳腺センター 
2) 関西医科大学香里病院 乳腺外科 
 
和文抄録： Pertuzumab は HER2 の細胞外ドメインに結合し、ダイマー形成を阻害するである。種々の試験において、
trastuzumab 単独よりも Pertuzumab を併用した方が病理学的完全奏効率(pCR)を有意に上昇すると報告されている。今回、
我々は HER2 陽性乳癌に対して Pertuzumab を用いた術前化学療法を行った。16 名の StageII～III の HER2 陽性乳患者に、
Pertuzumab、Trastuzumab、Docetaxel（75 mg/m2）4 コース、その後に FEC100 療法 4 コースを施行した。年齢は 45～76
歳で、T1、T2、T3 はそれぞれ 2 例、11 例、3 例、N0、N1 はそれぞれ 6 例、10 例であった。Luminal HER2 type、HER2 
enrich type ともに 8 例であった。すべての症例で予定された化学療法が完全施行できた。組織学的効果は Grade3、2b、1a、
1b がそれぞれ 11 例、3 例、1 例、1 例であった。pCR（ypT0/is + ypN0）率は 69％で、奏功率は 94%であった。Pertuzumab
による心機能障害等の副作用は認められなかった。 
キーワード： HER2 陽性乳癌、Pertuzumab、術前化学療法、pCR 
